Tutorials
NAS:BGNE (Cayman Islands)  
BeiGene Ltd logo

BeiGene Ltd

$ 193.97 -2.67 (-1.36%) 08:08 PM EST
P/E:
At Loss
P/B:
3.89
Market Cap:
$ 20.60B
Enterprise V:
$ 15.36B
Volume:
163.73K
Avg Vol (2M):
288.52K
Also Trade In:
Volume:
163.73K
Market Cap $:
20.60B
PE Ratio:
At Loss
Avg Vol (2-Month):
288.52K
Enterprise Value $:
15.36B
PB Ratio:
3.89
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

BeiGene Ltd
NAICS : 325412 SIC : 2834
c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108
Description
BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.
Name Current Vs Industry Vs History
Cash-To-Debt 9.02
Equity-to-Asset 0.72
Debt-to-Equity 0.12
Debt-to-EBITDA -0.34
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 4.83
Distress
Grey
Safe
Beneish M-Score -2.23
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 58.25
9-Day RSI 59.11
14-Day RSI 58.34
6-1 Month Momentum % -11.67
12-1 Month Momentum % -38.07

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.54
Quick Ratio 4.35
Cash Ratio 4.08
Days Inventory 41.72
Days Sales Outstanding 71.7
Days Payable 45.39

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -19.9

Financials (Next Earnings Date:2022-11-04 Est.)

BGNE's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:BGNE

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 1,068.617
EPS (TTM) ($) -20.451
Beta 0.43
Volatility % 43.65
14-Day RSI 58.34
14-Day ATR ($) 11.415635
20-Day SMA ($) 182.6055
12-1 Month Momentum % -38.07
52-Week Range ($) 118.18 - 426.56
Shares Outstanding (Mil) 103.82

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

BeiGene Ltd Filings

Document Form Filing Date
No Filing Data

Headlines

See More